Factors affecting the uptake of ‘similar biologics’ in India

Biosimilares/Investigación | Posted 08/01/2016 post-comment0 Post your comment

In his review of similar biologics in India, Dr Nagaraj Malipatil, a clinical pharmacologist from Bangalore, attempted to address what are the drivers and the limitations to the ‘similar biologics’ market in India [1].

23 AA011020

Factors facilitating the development and uptake of similar biologics in India, according to Dr Malipatil, include poor patent enforcement, less stringent regulatory requirements, low R & D costs and the low price of similar biologics. Partnerships for the development of similar biologics for the Indian market and biosimilars for the global market are also facilitating the development of both similar biologics and biosimilars.

Poor patent enforcement in India provides opportunities for domestic biologicals manufacturers, while public–private sector partnerships promote similar biologics development. The less stringent regulatory requirements and low R & D costs enable domestic biologicals to be priced much lower in India compared to originator biologicals, further driving uptake as well as offering huge potential for contract manufacturing of biosimilars for the global market and for exports. Domestic companies are also entering into partnerships with international players to facilitate the development of similar biologics for the Indian market and biosimilars for global markets.

However, restrictions to the uptake of similar biologics in India include the limited health insurance coverage in the country. This means that despite the low price of similar biologics compared to originator biologicals, there is still poor access to biologicals in the country. Issues over the quality and safety of some domestically manufactured similar biologics also remain a concern among patients and physicians.

There are currently similar biologics of nine of the top 10 brand-name biologicals available in India; with similar biologics of bevacizumab in development, see Table 1.

Table 1: Status of similar biologics for top 10 biologicals

Brand-name Active substance Originator company 2014 global sales US$ Status of similar biologic
Humira adalimumab AbbVie 12.5 Launched 2014 [2]
Remicade infliximab Johnson & Johnson 9.3 Launched 2014 [3]
Enbrel etanercept Amgen/Pfizer 8.3 Launched 2013 [4]
Avastin bevacizumab Roche 7.4    [5] Undergoing preclinical studies
Lantus insulin glargine Sanofi 6.8 Launched in 2009 [6]
Herceptin trastuzumab Roche 6.2 Launched in 2013 [7]
Neulasta pegfilgrastim Amgen 5.8 Launched in 2007 [8]
Rituxan rituximab Roche 5.5 Launched in 2007 [9]
Epogen epoetin alfa Amgen 3.2 Launched in 2001 [10]
Aranesp darbepoetin alfa Amgen 1.9 Launched in 2010 [11]

 

Conflict of interest
The authors of the research paper [1] declared that there were no conflicts of interest. 

Editor’s comment
It should be noted that ‘similar biologics’ approved in India might not have been authorized following as strict a regulatory process as is required for approval of biosimilars in the European Union. The EMA (European Medicines Agency) regulatory requirements ensure the same high standards of quality, safety and efficacy for biosimilars as for originator biologicals, and also include a rigorous comparability exercise with the reference product. 

Related articles
Safety concerns limit similar biologics uptake in India

Lack of health insurance limits access to biologicals in India

Partnerships driving similar biologics development in India

Domestic biologicals cost less in India

Low costs and less stringent regulatory requirements in India

Regulation and uptake of ‘similar biologics’ in India

References
1.    Malipatil NB, Haridas KM, Shruthi DP. Biosimilars and regulations: a review. J Pharm Biomed Sci. 2015;05(06):453-68.
2.    GaBI Online - Generics and Biosimilars Initiative. Biosimilars of adalimumab [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2016 Jan 8]. Available from: www.gabionline.net/Biosimilars/General/Biosimilars-of-adalimumab 
3.    GaBI Online - Generics and Biosimilars Initiative. Biosimilars of infliximab [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2016 Jan 8]. Available from: www.gabionline.net/Biosimilars/General/Biosimilars-of-infliximab
4.    GaBI Online - Generics and Biosimilars Initiative. Biosimilars of etanercept [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2016 Jan 8]. Available from: www.gabionline.net/Biosimilars/General/Biosimilars-of-etanercept 
5.    GaBI Online - Generics and Biosimilars Initiative. Biosimilars of bevacizumab [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2016 Jan 8]. Available from: www.gabionline.net/Biosimilars/General/Biosimilars-of-bevacizumab 
6.    GaBI Online - Generics and Biosimilars Initiative. ‘Similar biologics’ approved and marketed in India [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2016 Jan 8]. Available from: www.gabionline.net/Biosimilars/General/Similar-biologics-approved-and-marketed-in-India 
7.    GaBI Online - Generics and Biosimilars Initiative. Biosimilars of trastuzumab [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2016 Jan 8]. Available from: www.gabionline.net/Biosimilars/General/Biosimilars-of-trastuzumab 
8.    GaBI Online - Generics and Biosimilars Initiative. Biosimilars of pegfilgrastim [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2016 Jan 8]. Available from: www.gabionline.net/Biosimilars/General/Biosimilars-of-pegfilgrastim
9.    GaBI Online - Generics and Biosimilars Initiative. Biosimilars of rituximab [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2016 Jan 8]. Available from: www.gabionline.net/Biosimilars/General/Biosimilars-of-rituximab
10.   GaBI Online - Generics and Biosimilars Initiative. Biosimilars of epoetin alfa [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2016 Jan 8]. Available from: www.gabionline.net/Biosimilars/General/Biosimilars-of-epoetin-alfa
11.   GaBI Online - Generics and Biosimilars Initiative. Biosimilars of darbepoetin alfa [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2016 Jan 8]. Available from: www.gabionline.net/Biosimilars/General/Biosimilars-of-darbepoetin-alfa

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2016 Pro Pharma Communications International. All Rights Reserved.

Safety concerns limit similar biologics uptake in India
comment icon Comments (0)
Post your comment
Related content
Compras federales de medicamentos biológicos para el cáncer en Brasil
Cancer Cell V13I20
Biosimilares/Investigación Posted 24/09/2021
Long-term safety and efficacy of anti-TNF-α biosimilars in psoriasis
MD002152
Biosimilares/Investigación Posted 24/09/2021
Clinical development of biosimilars in the oncology setting
Cancer image015
Biosimilares/Investigación Posted 17/09/2021
Most viewed articles
Sobre GaBI
INICIO/Sobre GaBI Posted 05/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
INICIO/Directrices Posted 08/10/2010